Data
Click on Protocol Number of interest to view study-related documentation or download data files.
(DTMC data files are under development.)
| Division | Study Number | Title Sort ascending | Investigator(s) | Release Date |
|---|---|---|---|---|
| CTN | NIDA-CTN-0020 | Job Seekers Training for Patients with Drug Dependence | Dace Svikis, Ph.D. | Feb 27, 2009 |
| GRNT | NIDA-CENIC-P1S1 | Investigating the Impact of Nicotine Using Spectrum Cigarettes (P1S1) - Grant U54-DA031659 | Eric C. Donny, Ph.D. | Feb 14, 2020 |
| CTN | NIDA-CTN-0032 | HIV Rapid Testing and Counseling in Drug Abuse Treatment Programs in the U.S. | Lisa Metsch, Ph.D. | Nov 02, 2011 |
| CTN | NIDA-CTN-0017 | HIV and HCV Risk Reduction Interventions in Drug Detoxification and Treatment Settings | Robert Booth, Ph.D. | Dec 23, 2008 |
| CTN | NIDA-CTN-0051 | Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment | John Rotrosen, M.D. | Jan 12, 2018 |
| DTMC | NIDA-CPU-0005 | Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. | Louis Cantilena, Jr., M.D, Ph.D. | May 23, 2017 |
| DTMC | NIDA-CTO-0011 | Double-Blind, Placebo-Controlled, Dose Response Trial Of Ondansetron For The Treatment Of Methamphetamine Dependence | Bankole Johnson, DSc., M.D., Ph.D. | Jan 15, 2019 |
| DTMC | NIDA-CPU-0002 | Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers | Louis Cantilena, Jr., M.D, Ph.D. | May 23, 2017 |
| DTMC | NIDA-CSP-1019 | Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System For The Treatment Of Cocaine Dependence | Ahmed Elkashef, M.D., Paul J. Fudala, Ph.D. | May 07, 2018 |
| DTMC | NIDA-CTO-0005 | Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence | John D. Roache, Ph.D. | Aug 01, 2016 |